DDrare: Database of Drug Development for Rare Diseases

Searched query = "Alport syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = ACE I, ATA II and Statins; ACE-inhibitor; AT1-inhibitor; Atrasentan; BARDOXOLONE METHYL; Bardoxolone; Bardoxolone Methyl; Bardoxolone methyl; Benazepril; Benazepril, Valsartan and Fluvastatin; Delix; Fluvastatin; Gold; HMG-Coenzyme inhibitor (statin); Hydroxychloroquine; Lademirsen (SAR339375); Paricalcitol; RAMIPRIL; RG-012; RG012; RTA 402; Ramipril; Spironolactone; Valsartan

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01485978 (ClinicalTrials.gov)	March 2012	2/12/2011	Efficacy and Safety Study to Delay Renal Failure in Children With Alport Syndrome	Early Prospective Therapy Trial to Delay Renal Failure in Children With Alport Syndrome	Renal Insufficiency, Chronic	Drug: Ramipril;Drug: placebo to ramipril	Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH	University Medical Center Goettingen;German Federal Ministry of Education and Research	Completed	24 Months	18 Years	All	66	Phase 3	Germany
2	EUCTR2010-024300-10-DE (EUCTR)	27/02/2012	12/12/2011	Early prospective therapy trial to delay renal failure in children with Alport syndrome. - EARLY PRO-TECT Alport	Early prospective therapy trial to delay renal failure in children with Alport syndrome. - EARLY PRO-TECT Alport	Alport's syndrome MedDRA version: 19.1;Level: PT;Classification code 10001843;Term: Alport's syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]	Trade Name: Delix Product Name: Delix Other descriptive name: RAMIPRIL	University Medical Center Göttingen	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes		Phase 3	Germany

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT01485978
(ClinicalTrials.gov)

March 2012

2/12/2011

Efficacy and Safety Study to Delay Renal Failure in Children With Alport Syndrome

Early Prospective Therapy Trial to Delay Renal Failure in Children With Alport Syndrome

Renal Insufficiency, Chronic

Drug: Ramipril;Drug: placebo to ramipril

Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH

University Medical Center Goettingen;German Federal Ministry of Education and Research

Completed

24 Months

18 Years

All

Phase 3

Germany

EUCTR2010-024300-10-DE
(EUCTR)

27/02/2012

12/12/2011

Early prospective therapy trial to delay renal failure in children with Alport syndrome. - EARLY PRO-TECT Alport

Alport's syndrome
MedDRA version: 19.1;Level: PT;Classification code 10001843;Term: Alport's syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]

Trade Name: Delix
Product Name: Delix
Other descriptive name: RAMIPRIL

University Medical Center Göttingen

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 3

Germany